Cargando…

Risk of relapse of multiple myeloma following kidney transplantation

BACKGROUND: Autologous stem cell transplantation (ASCT) and novel therapies have improved the prognosis for patients with multiple myeloma (MM). For those who undergo ASCT while on dialysis, a similar survival compared with the overall MM population has been reported. Therefore, for patients achievi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Sapna, Ibrahim, Maria, Delaney, Michael, Schey, Steve, Bygrave, Ceri, Streetly, Matthew, Benjamin, Reuben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Onconephrology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452174/ https://www.ncbi.nlm.nih.gov/pubmed/30976399 http://dx.doi.org/10.1093/ckj/sfy137

Ejemplares similares

Multiple myeloma and kidney transplantation: the beginning of a new era
por: Van den bosch, Ines, et al.
Publicado: (2019)

Intensive haemodialysis using PMMA dialyser does not increase renal response rate in multiple myeloma patients with acute kidney injury
por: Hudier, Laurent, et al.
Publicado: (2018)

Treatment of multiple myeloma with renal involvement: the nephrologist’s view
por: Favà, Alexandre, et al.
Publicado: (2018)

Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network
por: Sprangers, Ben, et al.
Publicado: (2018)

Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network
por: Wanchoo, Rimda, et al.
Publicado: (2016)

Haematological malignancies and acute kidney injury requiring nephrology consultation: challenging the worst of the worst
por: Chuva, Teresa, et al.
Publicado: (2016)

Comparison of trends in colorectal cancer screening in the US end-stage renal disease population and the US Medicare population
por: Fwu, Chyng-Wen, et al.
Publicado: (2016)

Early detection of acute cisplatin nephrotoxicity: interest of urinary monitoring of proximal tubular biomarkers
por: Bunel, Valérian, et al.
Publicado: (2017)

Type B lactic acidosis from fluorouracil in fluorouracil, oxaliplatin and leucovorin treatment for carcinoma of the colon in a hemodialysis patient
por: Yeung, Emily K, et al.
Publicado: (2018)

Renal involvement in chronic lymphocytic leukemia
por: Wanchoo, Rimda, et al.
Publicado: (2018)

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
por: Murakami, Naoka, et al.
Publicado: (2016)

A new expression of immune checkpoint inhibitors’ renal toxicity: when distal tubular acidosis precedes creatinine elevation
por: Charmetant, Xavier, et al.
Publicado: (2019)

Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option
por: Lazana, I., et al.
Publicado: (2022)

Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy
por: Cook, Gordon, et al.
Publicado: (2020)

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
por: Jagannath, Sundar, et al.
Publicado: (2021)

Survival from multiple myeloma in England and Wales up to 2001
por: Schey, S
Publicado: (2008)

Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia
por: Cook, Gordon, et al.
Publicado: (2021)

Kidney Transplant Outcomes of Patients With Multiple Myeloma
por: Heybeli, Cihan, et al.
Publicado: (2022)

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
por: Vincent, L, et al.
Publicado: (2015)

Pericardial relapse of multiple myeloma
por: Jamison, Lee S, et al.
Publicado: (2020)

Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
por: Metelo, Ana M., et al.
Publicado: (2022)

Kidney Rejection Following Simultaneous Liver-kidney Transplantation
por: Shah, Sapna, et al.
Publicado: (2020)

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2014)

Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
por: Ehsan, Hamid, et al.
Publicado: (2021)

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
por: Schey, Steve, et al.
Publicado: (2017)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Cutaneous involvement in relapsed multiple myeloma
por: Salle, Valéry, et al.
Publicado: (2022)

A Focus on Relapsed Multiple Myeloma
por: Noonan, Kimberly, et al.
Publicado: (2022)

Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2020)

P863: AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Searle, Emma, et al.
Publicado: (2023)

Relapsed Multiple Myeloma Presenting as Intracranial Plasmacytoma and Malignant Pericardial Effusion following Recent Allogeneic Stem Cell Transplantation
por: Pan, Jonathan, et al.
Publicado: (2017)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Kidney transplantation for active multiple myeloma or smoldering myeloma: a case–control study
por: Kormann, Raphaël, et al.
Publicado: (2019)

Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
por: Park, Hyunkyung, et al.
Publicado: (2020)

Kidney Transplantation in Patients With Active Multiple Myeloma: Case Reports
por: Lum, Erik Lawrence, et al.
Publicado: (2017)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
por: Bhatt, Parva, et al.
Publicado: (2023)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nqgc63ustenpspppo28t1jh8nd